Analyst Coverage

Disclaimer: Any opinions, estimates or forecasts regarding ResApp Health Limited’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ResApp Health Limited or its management. ResApp Health Limited does not by its reference to any analysts imply its endorsement of or concurrence with such information, conclusions or recommendations.

June 9, 2017
Martyn Jacobs, Patersons Securities – Market Update

March 1, 2017
Martyn Jacobs, Patersons Securities – 1H17 Result, Waiting on FDA Trial Data

November 16, 2016
Martyn Jacobs, Patersons Securities – Initiating Coverage

August 19, 2016
Bioshares Edition 661

July 25, 2016
Stuart Roberts, NDF Research – Initiation of Coverage

April 4, 2016
Michael Eidne, DJ Carmichael – Emerging ASX Technology Sector

October 19, 2015
Michael Eidne, DJ Carmichael – Emerging ASX Technology Sector

October 9, 2015
Bioshares Edition 620

August 28, 2015
Bioshares Edition 614

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2016 ResApp Health Limited. All Rights Reserved.


+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations



Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.